JPS6025928A - Drug - Google Patents

Drug

Info

Publication number
JPS6025928A
JPS6025928A JP13337683A JP13337683A JPS6025928A JP S6025928 A JPS6025928 A JP S6025928A JP 13337683 A JP13337683 A JP 13337683A JP 13337683 A JP13337683 A JP 13337683A JP S6025928 A JPS6025928 A JP S6025928A
Authority
JP
Japan
Prior art keywords
sodium tungstate
lipid peroxide
cataract
arteriosclerosis
main component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13337683A
Other languages
Japanese (ja)
Inventor
Kaoru Kase
加瀬　薫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP13337683A priority Critical patent/JPS6025928A/en
Publication of JPS6025928A publication Critical patent/JPS6025928A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide a drug containing an aqueous solution of sodium tungstate as a main component, capable of reducing the lipid peroxide in the blood, and remarkably effective for the prevention and remedy of diseases caused by the excess lipid peroxide, e.g. cataract, arteriosclerosis, cardiopathy, etc. CONSTITUTION:The present drug contains 1-3% aqueous solution of sodium tungstate as a main component, and is effective for the prevention and remedy of diseases caused by excess lipid peroxide, e.g. cataract, arteriosclerosis, cardiopathy, diabetes, gastric ulcer, etc. Especially in cataract, the remedying effect can be further improved by applying the solution of sodium tungstate directly to the eye. Sodium tungstate exhibits remarkable drug action by reducing the lipid peroxide to the original unsaturated fatty acid.

Description

【発明の詳細な説明】 本発明は血液中の過酸化脂質の量が過大になることが主
因とされる疾患、例えば白内障、動脈硬化、心臓障害、
糖尿病、胃潰瘍、腸潰瘍、歯槽膿漏などに用いて顕著な
薬効を有する新規な薬剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention deals with diseases mainly caused by an excessive amount of lipid peroxide in the blood, such as cataracts, arteriosclerosis, heart disorders,
This invention relates to a new drug that has remarkable medicinal effects for diabetes, gastric ulcers, intestinal ulcers, alveolar pyorrhea, etc.

そもそも、白内障、動脈硬化、心臓障害、糖尿病、胃潰
瘍、腸潰瘍、歯槽膿漏などの疾患は血液中の過酸化脂質
が過大となることに起因するものであることは医学界の
定説となっており、例えば、白内障については、患液中
に増えた過酸化脂質が眼の水晶体に栄養を送る前房水の
中に運び込まれて水晶体を傷っけ、水晶体が濁って視力
を失うという発症の機構が解明されている。It is a well-established theory in the medical world that diseases such as cataracts, arteriosclerosis, heart disorders, diabetes, gastric ulcers, intestinal ulcers, and alveolar pyorrhea are caused by an excessive amount of lipid peroxide in the blood. For example, in the case of cataracts, lipid peroxide that increases in the affected fluid is carried into the anterior aqueous humor that supplies nutrients to the lens of the eye, damaging the lens and causing clouding of the lens and loss of vision. The mechanism has been elucidated.

そして、本発明の発明者はタングステン酸ナトリューム
にこのような過酸化脂質を還元して元の不飽和脂肪酸に
戻す作用があることを発見し、このタングステン酸ナト
リュームを内服することによって血液中の過酸化脂質を
減少し前記の諸疾患の予防や進行の抑制若しくは治癒を
期し得ること、また、特に白内障については同タングス
テン酸テトリュームを直接、点眼することによって上記
の治癒効果を一層高め得ることを多数の臨床例によって
確認することができた。The inventor of the present invention discovered that sodium tungstate has the effect of reducing such peroxidized lipids and returning them to their original unsaturated fatty acids, and by taking this sodium tungstate orally, the excess lipids in the blood can be reduced. It has been shown that oxidized lipids can be reduced to prevent, inhibit the progression of, or cure the various diseases mentioned above, and that, especially for cataracts, the above-mentioned healing effects can be further enhanced by directly instilling tungstate tetolium into the eyes. This could be confirmed by clinical examples.

本発明は上記の諸疾患の病理とタングステン酸ナトリュ
ームの上記の特性の発見に基いて創出されたものであっ
て、タングステン酸ナトリュームの１〜３Ｌ％水溶液を
主成分とすることを特徴とするのでこれを内服剤として
用いるときには上記の白内障、動脈硬化、心臓障害、糖
尿病、胃潰瘍、腸潰瘍、歯槽膿漏などの治癒に特効があ
り、またこれを点眼剤として用いるときには白内障の治
癒に顕著な薬効を奏する効果がある。The present invention was created based on the pathology of the above-mentioned diseases and the discovery of the above-mentioned properties of sodium tungstate, and is characterized in that the main component is a 1-3L% aqueous solution of sodium tungstate. When used as an internal medicine, it has a specific effect on curing the above-mentioned cataracts, arteriosclerosis, heart disorders, diabetes, gastric ulcers, intestinal ulcers, alveolar pyorrhea, etc., and when used as eye drops, it has a remarkable medicinal effect on curing cataracts. It has the effect of playing.

（実施例） タングステン酸ナトリューム（ソーダ）を一度沸謄させ
た湯１００　ｃｃに２〜３ｇの割合で溶かし、この溶液
を２４時間放置してから濾紙で濾過して内服剤　若しく
は点眼剤を得る。(Example) Sodium tungstate (soda) is dissolved in 100 cc of boiled water at a rate of 2 to 3 g, and this solution is left to stand for 24 hours and then filtered through a filter paper to obtain an internal medicine or eye drops.

（尚、この内服剤は例えば、胃又は腸潰瘍の場合は一日
一回、朝の空腹時に２０ｃｃずつ連続して飲用すると効
果的であり、貞だ点眼剤は一日三回、−回に一滴ずつ連
続して点眼すると効果的である。） 特許出願人　出　中　精之助(In addition, for example, in the case of stomach or intestinal ulcers, this oral preparation is effective if taken once a day on an empty stomach in the morning in 20 cc portions, and for the chaste eye drops three times a day, It is effective when applied one drop at a time to the eye.) Patent applicant: Seinosuke Izunaka

Claims (1)

【特許請求の範囲】[Claims] タングステン酸ナトリュームの１〜３％水溶液を主成分
とすることを特徴とする薬剤。A drug characterized by containing a 1-3% aqueous solution of sodium tungstate as a main component.
JP13337683A 1983-07-21 1983-07-21 Drug Pending JPS6025928A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13337683A JPS6025928A (en) 1983-07-21 1983-07-21 Drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13337683A JPS6025928A (en) 1983-07-21 1983-07-21 Drug

Publications (1)

Publication Number Publication Date
JPS6025928A true JPS6025928A (en) 1985-02-08

Family

ID=15103283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13337683A Pending JPS6025928A (en) 1983-07-21 1983-07-21 Drug

Country Status (1)

Country Link
JP (1) JPS6025928A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755681A1 (en) * 1995-07-19 1997-01-29 Quimica Farmaceutica Bayer, S.A. Tungsten (VI) compositions for the oral treatment of diabetes mellitus
ES2108642A1 (en) * 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Tungsten (vi) composition for peroral treatment of diabetes mellitus
WO2002098435A1 (en) * 2001-05-16 2002-12-12 Química Farmacéutica Bayer, S.A. Oral compositions for the treatment of obese, non-diabetic mammals, including humans

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755681A1 (en) * 1995-07-19 1997-01-29 Quimica Farmaceutica Bayer, S.A. Tungsten (VI) compositions for the oral treatment of diabetes mellitus
ES2108642A1 (en) * 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Tungsten (vi) composition for peroral treatment of diabetes mellitus
WO2002098435A1 (en) * 2001-05-16 2002-12-12 Química Farmacéutica Bayer, S.A. Oral compositions for the treatment of obese, non-diabetic mammals, including humans
ES2187276A1 (en) * 2001-05-16 2003-05-16 Quimica Farm Bayer Sa Oral compositions for the treatment of obese, non-diabetic mammals, including humans
US7122209B2 (en) 2001-05-16 2006-10-17 Quimica Farmaceutica Bayer S.A. Oral compositions for the treatment of non-diabetic obese mammals, including humans

Similar Documents

Publication Publication Date Title
DE701443T1 (en) Terfanadine metabolites and their optically pure isomers for the treatment of allegic diseases
JPH09504543A (en) Cataract prevention methods and preventive measures
US4302471A (en) Method of treating cardiac and renal failures
EP0275457A2 (en) Solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate
Scott et al. Ocular changes in the Bloch-Sulzberger syndrome (incontinentia pigmenti)
TW397685B (en) Pharmaceutical composition for prophylaxis and traetment of retinal diseases
Di Benedetto Chronic hypervitaminosis A in an adult
ATE6645T1 (en) DIBENZOXAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPS6025928A (en) Drug
JPS6025916A (en) Bathing water
Gerstle et al. Marginal corneal ulceration (limbal guttering) as a presenting sign of temporal arteritis
Kniskern Cataracts following dinitrophenol
Cohen et al. Toxic epidermal necrolysis
US3995057A (en) Ophthalmological method
JPS62223117A (en) Ophthalmic solution for keratopathy
JPH0641409B2 (en) Ophthalmic solution
EP0402208A1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
Gelfand Gastrointestinal bleeding during tolbutamide therapy
JPH07233062A (en) Composition for treating skin pruritus of patient requiring artificial dialysis and composition for treating hyperparathyroidism
Hall et al. Failure of epsilon-aminocaproic acid in the treatment of scleroderma.
JPH05502439A (en) eye drops
JPH0625062B2 (en) Steroid cataract prevention and treatment
Rachmilewitz et al. Electrocardiographic changes and the effect of niacin therapy in pellagra
Lagrange Derangements of the organo-vegetative nervous system and of the endocrinian system in essential glaucoma
Senft et al. Salmonella endophthalmitis in an infant with presumed retinopathy of prematurity